- Price
- $247.18
- Day
- -0.58%
- Mkt Cap
- $57.89B
- 52W Range
- $145.87 – $258.30
- Volume
- 1.54M
- Beta
- 0.52
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read full article
Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.
Read full article
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Read full article
Connor Clark and Lunn Investment Management Ltd. bought a new position in shares of Cardinal Health, Inc. (NYSE: CAH) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,554 shares of the company's stock, valued at approximately $844,000. Other large investors also
Read full article
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read full article
Algert Global LLC grew its holdings in shares of Cardinal Health, Inc. (NYSE: CAH) by 246.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 36,993 shares of the company's stock after purchasing an additional 26,330 shares during the quarter.
Read full article
CAH enters fiscal 2027 with strong specialty growth, but IRA pricing changes, GMPD challenges and heavy CapEx pose risks.
Read full article
The sale realized $7.0 million based on a weighted average execution price. The transaction represents a 47% reduction in Mayer direct equity holdings.
Read full article
The sale involved 2,302 shares at $237.39 per share, resulting in a transaction value of $546,500. All shares were held directly; no indirect ownership through entities or trusts was disclosed in the filing.
Read full article
The disposition involved 11,650 shares at a weighted average price of $235.72, totaling approximately $2.7 million. Greene executed the sale directly and maintains no indirect equity holdings through trusts or other legal entities.
Read full article
Deborah Weitzman sold 7,354 shares for approximately $1.7 million on August 18. The entire disposition was executed through direct ownership, with no indirect holdings reported in the filing.
Read full article
The disposition of 35,000 shares on August 18 generated a total transaction value of $8.3 million. The transaction involved exclusively directly held shares, with the insider reporting no indirect ownership in this filing.
Read full article